COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

ABSTRACT: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe C

SUBMITTER: Chatzikonstantinou T 

PROVIDER: S-EPMC8559135 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature